Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Amanta Healthcare IPO Review, Analysis, Good or Bad

By Jagat Joshi
September 1, 2025

The opening date of the Amanta Healthcare IPO is September 1, 2025, while the closing date is September 3, 2025. The Amanta Healthcare IPO price band is set between ₹120 to ₹126 per share. At the same time, the face value of the IPO is ₹10 each. The company filed a DRHP to raise funds of around ₹126 crores through an Initial public offering (IPO).

As an investor, deciding whether the IPO is Good or Bad to invest in can often be challenging. If you are confused and worried about whether to Apply or Not the Amanta Healthcare IPO. Then worry not, here we are describing 10 important key points & an in-depth, detailed Amanta Healthcare IPO review which will help you to make the decision.

Strengths and Weaknesses of Amanta Healthcare IPO

Strengths:

Amanta Healthcare is a well-established manufacturer of pharmaceutical formulations with a wide product range and presence in diverse markets.
The company includes an experienced management team and promoters who have over 30 years of experience in the pharmaceutical industry.
The company comprises of having a large manufacturing capability spread over 66,852.00 sq meters of land located at village Hariyala, District Kheda, Gujarat, India.

Weaknesses:

It’s all products made at the manufacturing facility are located at Hariyala village, Kheda district, Gujarat. Any delay or shutdown at the facility due to issues like power or water shortage, natural disaster, accidents, or machinery breakdowns can badly impact the business, cash flow, and financial condition.
The company may not be able to improve its profit margins and profits in the future.
In FY 2025, 45.78%, 57.25% in FY 2024, and 62.64% in FY 2023, the company’s finance cost has been very high. Meaning if the company does not reduce these costs in the future, then it can badly impact the business, financial condition, and cash flow.
In the past, their manufacturing license was suspended. If suspensions happen again in the future can negatively impact the business, cash flow, and financial condition.

Amanta Healthcare IPO Review

IPO Watch: May Apply
Invest4Edu Private Limited: Apply
Scoop Investment: May Apply
Exencial Research Partners: May Apply
Minerva Capital Research Solutions: May Apply
Capital Market: Avoid

Amanta Healthcare IPO Details

IPO Size	₹126 crores
Offer-for-sale	No Offer-for-Sale
Fresh issue	₹126 crores
Price band	₹120 to ₹126
Subscription	Opens on September 1, 2025, and the closing date is September 3, 2025
Purpose of IPO	Fresh Issue and No Offer-for-Sale

Amanta Healthcare IPO Open and closing dates?

Amanta Healthcare IPO will open for subscription on September 1, 2025, and will be closed for subscription on September 3, 2025.

What is the size of the Amanta Healthcare IPO?

The company planned to raise around ₹126 crores in funds via IPO. This IPO comprises a fresh issue of ₹126 crores with no Offer-for-Sale component with a face value of ₹10 each.

What are the subscription details of the Amanta Healthcare IPO?

The Amanta Healthcare IPO price range is set at ₹120 to ₹126 per share. In this IPO, a total of 119 shares were available in 1 lot size for the minimum Retail category. For the maximum Retail category, 1,547 shares were available in 13 lot sizes. Additionally, 1,666 shares were available in 14 lot sizes for the S-HNI Minimum category. While for the B-HNI Minimum category, 7,973 shares were available in 67 lot sizes.

To invest in this IPO, each investor category has specific investment amounts:

Retail Investors: Minimum investment of ₹14,994 and maximum investment of ₹1,94,922.
Small HNI (S-HNI): Minimum investment of ₹2,09,916.
Big HSI (S-HNI): A minimum investment of ₹10,04,598 is required.

What is the Amanta Healthcare IPO listing Date?

Amanta Healthcare is a Mainboard IPO. Shares will be listed on September 8, 2025, on the BSE (Bombay Stock Exchange) & NSE (National Stock Exchange).

About Amanta Healthcare

Incorporated in December 1994, Amanta Healthcare Limited is one of the growing pharmaceutical companies engaged in the development, manufacturing, and marketing of a comprehensive range of sterile liquid products, mainly parenterals. The company is involved in the making of IV fluids, diluents, eye drops, and respiratory care solutions. These are packed in plastic containers using advanced Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies.

As of March 31, 2025, the company employs a total of 1,718 employees. Under its medical devices segment, Amanta Healthcare also offers irrigation solutions, first-aid items, and eye lubricants. Under its own brand, the company makes over 45 generic products and sells them in India, through 320 distributors and stockists.

What are the Objectives of the Amanta Healthcare Limited IPO?

The proceeds raised from the fresh issue will be utilized to handle the capital expenditure requirements for civil construction work and towards the purchase of equipment, plant, and machinery for setting up a new manufacturing line of SteriPort at Hariyala, Kheda, Gujarat. Some proceeds will be used towards civil construction work, purchase of equipment, plant, and machinery, and setting up a new manufacturing line for SVP at Hariyala, Kheda, Gujarat. Lastly, the remaining funds will be used for the company’s General Corporate Purposes.

Amanta Healthcare IPO Financials

In 2024, the company generated a revenue of ₹13,946.01 crores against ₹2,690.46 crores in 2023. In 2024, reported a profit of ₹5,245.39 crores against a profit of ₹231.11 crores in 2023.

Amanta Healthcare IPO Promoters

Bhavesh Patel, Vishal Patel, Jayshreeben Patel, Jitendra Kumar Patel, and Milcent Appliances Private Limited are the promoters of the company.

Who are the Amanta Healthcare IPO lead managers and registrar?

Beeline Capital Advisors Pvt Limited is the issue’s lead manager, while MUFG Intime India Pvt Ltd is the company’s registrar.

Should you apply or not for the Amanta Healthcare IPO?

Amanta Healthcare is launching an IPO that is comprised of only a fresh issue, with no offer-for-sale component. The company has set a price band of ₹120 to ₹126 per share and a plan to raise around ₹126 crores via IPO. It is one of the leading pharmaceutical companies engaged in the development, manufacturing & marketing of a wide range of Sterile Liquid products. As of the DRHP filing date, the company has a portfolio of 47 products across 120 international jurisdictions.

If we talk about the company’s financials, in FY25, Amanta reported an EBITDA of ₹59.7 crore, showcasing a rise of 3.8% from the previous year. The proceeds raised from the fresh issue will be utilized for the funding of new manufacturing lines and other corporate needs. The company incorporates technologies, including ABFS and ISBM, for sterile liquid and parenteral formulations production. Expanding the National Sales network, increasing business from existing customers, and adding new customers are some of the strategies the company will be following in the future.

So, now the question is, should you apply or not for the Amanta Healthcare IPO? If you are looking to invest in a company that promotes client relationships, a highly diversified customer base, and a proven track record of consistent growth, Rising EBITDA and margins signal stronger operating efficiency, then Amanta Healthcare’s IPO could be a good long-term investment option.

However, we recommend always doing a good financial background check on the company you want to invest in, and investing in it at your own risk.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.